Effects of exercise on doxorubicin-induced chronic cardiotoxicity in a juvenile rat model
by Lien, Chia-Ying, Ph.D., UNIVERSITY OF NORTHERN COLORADO, 2010, 127 pages; 3415983

Abstract:

Doxorubicin (DOX) is the most common anticancer agent prescribed to treat childhood cancers. Utilization of DOX is limited by a dose-dependent cardiotoxicity that can eventually progress to heart failure. It has been suggested that children are more susceptible to develop chronic heart failure than adults. However, the majority of DOX studies were focused on acute cardiotoxicity in adult animals. Additionally, the exact cumulative dose of DOX that would cause chronic cardiac dysfunction in juvenile rats was undetermined. Recent studies have reported exercise training attenuated DOX-induced acute cardiotoxicity in adult rats. Therefore, the purpose of this study was to determine whether exercise rehabilitation could attenuate DOX-induced cardiac dysfunction in juvenile rats. To better understand the mechanisms that may cause chronic cardiac dysfunction, myosin heavy chain (MHC) distribution and sarco-(endo)-plasmic reticulum calcium-ATPase-2a (SERCA2a) protein expression were examined. Twenty-five-day old male Sprague Dawley pups were randomly assigned to either voluntary wheeling (WR) or sedentary (SED) groups. Immediately following the exercise assignment, rats were randomly assigned to receive either saline (WR+SAL and SED+SAL) or DOX (WR+SAL and WR+DOX). Rats in the DOX groups received i.p. injections of DOX (2mg/kg/day) for 7 consecutive days (14mg/kg cumulative). Rats assigned to SAL groups received an equivalent volume of SAL. In vivo cardiac function was monitored weekly using echocardiography to determine if cardiac dysfunction was present. Nine weeks after completed DOX treatment, cardiac function was assessed, and left ventricular tissue was analyzed for MHC isoform distribution and SERCA2a protein expression. The SED+DOX rats had significant in vivo diastolic dysfunction and ex vivo diastolic and systolic dysfunction when compared to SED+SAL animals However, no in vivo or ex vivo cardiac dysfunction was found in WR+DOX animals, suggesting that exercise prevented DOX-induced cardiac dysfunction. β-MHC isoform distribution and SERCA2a expression of SED+DOX rats were not different from SED+SAL rats, suggesting that SERCA2a andβ3-MIIC isoform distribution may not contribute to DOX-induced diastolic and systolic dysfunction or the cardioprotective mechanisms of exercise in the juvenile rat model.

 
AdviserReid Hayward
SchoolUNIVERSITY OF NORTHERN COLORADO
SourceDAI/B 71-08, p. , Aug 2010
Source TypeDissertation
SubjectsPhysical therapy; Physiology; Oncology
Publication Number3415983
Adobe PDF Access the complete dissertation:
 

» Find an electronic copy at your library.
  Use the link below to access a full citation record of this graduate work:
  http://gateway.proquest.com/openurl%3furl_ver=Z39.88-2004%26res_dat=xri:pqdiss%26rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation%26rft_dat=xri:pqdiss:3415983
  If your library subscribes to the ProQuest Dissertations & Theses (PQDT) database, you may be entitled to a free electronic version of this graduate work. If not, you will have the option to purchase one, and access a 24 page preview for free (if available).

About ProQuest Dissertations & Theses
With over 2.3 million records, the ProQuest Dissertations & Theses (PQDT) database is the most comprehensive collection of dissertations and theses in the world. It is the database of record for graduate research.

The database includes citations of graduate works ranging from the first U.S. dissertation, accepted in 1861, to those accepted as recently as last semester. Of the 2.3 million graduate works included in the database, ProQuest offers more than 1.9 million in full text formats. Of those, over 860,000 are available in PDF format. More than 60,000 dissertations and theses are added to the database each year.

If you have questions, please feel free to visit the ProQuest Web site - http://www.proquest.com - or call ProQuest Hotline Customer Support at 1-800-521-3042.